Tyratech (DI) Share Discussion Threads

[mudbath] 09/5/2017 07:38

I agree with you across the board there PUGUGLY.
Tyratech,in splitting itself into two divisions, could be preparing for the sale of one or both.
It looks as though their foray into France came to naught.

[pugugly] 09/5/2017 07:28

Growth seems painfully slow in spite of what appear to be strong maketing efforts. Good market penetration apparent but nothing yet I can find on re orders. Big question is how much of the increase in ex factory due to placement of SKU's. Unlike Nobby not sure if it will be a Blue day. However the Vamousse brand has value but really should be with a very much bigger player - $64K question is how much would it be worth in a trade sale -

[ferris_bueller] 09/5/2017 07:22

Results for the Year Ended 31 December 2016
Tue, 9th May 2017 07:00

RNS Number : 5248E
TyraTech, Inc.
09 May 2017
 
Strictly Embargoed until 07.00: 9th May 2017
 
TyraTech, Inc.
("TyraTech" or the "Company")
Results for the Year Ended 31 December 2016
 
TyraTech Inc. (AIM: TYR, and TYRU), a life sciences company focused on nature-derived insect and parasite control products, today announces its results for the year ended 31 December 2016.
Operational highlights
•     Vamousse® sales in US grew by 10% to $5.9 million over 2015 and gained 3% points of market share
•    Vamousse sales in UK grew by 27% to £1.3 million in local currency (2015: £1 million) and gained market share over competition
•    Vamousse distribution network increased in the US - driven by the addition of Rite Aid, the third largest pharmacy chain in the US with more than 4,500 stores
•    Addition of 450 Morrisons stores, the fourth largest chain of supermarkets in the UK
•      Vamousse Head Lice Treatment was voted in the UK Pharmacy Product of the Year 2017 - Best Advertising Campaign by Independent Pharmacy Magazine
•      Launch of two new PureScience™ animal health products for the poultry and swine market in the US
 
Financial Highlights
 
•    Gross revenue increased to $8.4 million (FY2015: $7.4 million)
•    Gross product revenue increased by 13% to $8.0 million (2015: $7.1 million)
•    Gross profit increased to $4.8 million with gross margins on net revenue of 67% (2015: $4.6 million and 69%)
•    Vamousse generated a positive direct contribution of $2.2 million on $6.6 million net sales
•    Operating costs and expenses $7.1 million (2015: $7.1 million)
•    Net loss, before and after taxes, $2.3 million (2015: $2.3 million)
•    Cash and cash equivalents at 31 December 2016 $1.8 million (2015: $4.0 million)
•    Net cash used in operations decreased to $1.8 million (2015: $2.8 million)
 
Post period highlights
 
·     Addition of the new product Vamousse Lice Repellent at CVS and Meijer in the US
·     Distribution of Guardian® in the US in a limited test market (around 600 stores) with Kroger, the largest grocery store chain and supermarket by retail sales
·    Full launch of the equine fly repellent Outsmart™ with our partner SmartPak
 
Strategic Review
The Company has made significant progress in successfully commercializing its technology in both the human health space (Vamousse) and more recently, in the animal health space (PureScience and Outsmart).  With Vamousse, the Company has created a brand with a strong distribution network, a sizable market share and a positive direct contribution margin. With PureScience and Outsmart, the Company has begun to enter the animal health market, answering unmet needs, receiving positive customer feedback and completing efficacious field trials.
However, the Board is of the view that the Company lacks the necessary resources from operating cash flow alone to fund the next phase of its growth in both areas.  The increasingly positive cash contribution of the Vamousse product range cannot currently support the financial needs of Vamousse's growth as well as the development of the highly attractive animal health pipeline of new products.
Therefore, as announced on 9 February 2017, the Board implemented a strategic review to determine the most effective way to unlock the future growth potential of the Company's assets and maximize shareholder value.
The Board has now completed the first stage of this review and has concluded that it should divide the Company's intellectual property and products into two separate entities, focused on human health and animal health respectively.  Initially, both entities will remain 100% owned by Tyratech.
 
The human health business as a stand-alone entity could be profitable with growth potential in existing markets, geographical extension, and further innovative products. Investment in this business would be focused on supporting its own marketing and commercial initiatives and could be managed within limited cash resources depending on how aggressive a growth target is set.
 
The animal health business ultimately has larger growth opportunities, but will require further investment to support activities in research and development. This investment includes the necessary time to fully develop and transform the pipeline into marketable products. The Company believes that the resource requirements to build a successful animal health business would be significant and therefore require some type of private partnership and/or investment.
 
The Company is moving swiftly to complete the next stage of the strategic review process. It has engaged consultants to assist in the process with the aim of completing the reorganization by the end of the financial year. It is already in the final stages of an external validation of the value of Vamousse and in the early stages of an external validation of the valuation of the animal health business.
To optimize our existing resources, the Company will stay focused in the short term on growing Vamousse in the US and in the UK without major expansion in existing and new geographies. We will also continue to roll-out the existing animal health products in the US.
 
Commenting on results José Barella, Chairman TyraTech said:
"2016 was a challenging year for the Company. The progress made by Vamousse in difficult market conditions and the launch of the first products in the Animal Health space were significant but not enough to generate the cash resources to fully develop the potential of the Vamousse product range while investing in the R&D of a promising Animal Health pipeline. This situation masks the fact that, on a stand- alone basis, Vamousse, provides a positive business contribution.    
"To address this situation, the Board has undertaken a comprehensive review of the company structure, resource, and potential pipeline to unlock the full value of the Company for the shareholders.  Phase one of this is already complete and we look forward to updating shareholders further in due course."
Bruno Jactel, CEO TyraTech added:
"Despite difficult market conditions in the US, the overall gross revenues grew 13% year over year mainly driven by Vamousse. The brand made substantial progress in 2016, increasing its market share and retail distribution in the UK and in the US. We added a major distributor, Rite Aid, in the US and placed new products in CVS and gained commitment to expand the offering at Walgreens in 2017. From our innovation pipeline, we launched a new head lice repellent in 2017, which will extend our footprint into the prevention market where we believe significant growth opportunities exist. Despite our focus in resource allocation and management time on Vamousse, we advanced, albeit modestly, the pipeline of our animal health products. We launched products in the equine and poultry segments with major distributors and the biggest producers of poultry and eggs in the US. It also became apparent in 2016 that the Company does not have sufficient resources from operating cash flow alone to fund the next phase of its growth and unlock the full value of its assets. Our focus will be to continue to drive the growth of the Vamousse brand and the existing Animal Health products within the cash resources available and to implement the initial actions of the strategic review as we seek to unlock the full value of the Company for shareholders.
 
 
-ends-

[nobbygnome] 09/5/2017 07:15

Well no nasty surprises michael on a quick read! On the face of it splitting into 2 divisions looks like a good idea but we need to see the detail. Sales in the U.K. grew 27% despite Harold's protestations. There is a new Vamousse product, the animal health products, OutSmart and Guardians are all making progress....so it seems to me a market cap of about £6 million is completely ridiculous. The price could double today and the valuation would not look stretched.

Who knows on AIM but it should be a blue day as affairs I am concerned....

GLA

[michaelsadvfn] 08/5/2017 16:10

Let us hope they don't have anything else negative to relay to shareholders tomorrow, it seems that every news release is accompanied by something negative. If it's not an unseasonal decline in lice infestations or currency fluctuations or they won't meet analysts expectations.

We need to hear something positive for a change.

[nobbygnome] 08/5/2017 13:10

Another flipper I see....and no it isn't me!

Nobby

[michaelsadvfn] 08/5/2017 10:45

Strangely quiet considering results & a business update tomorrow, thought we may have seen a few punters out today.

I fully expect a rollercoaster ride tomorrow given the amount of shares that were bought at the 2p level on the AIM punting market. We've never hit 2.25p on the bid since.

[mudbath] 07/5/2017 12:47

Maybe Spreadex have been rolling over all or part of their declared 8,650,000 share holding for some time now.
That holding was most recently traded back in March,3,600,000 @ 1.75 on the 16th and 5,050,000 again @ 1.75 on the 8th.
Strangely those 3,600,000 were sold just 45 minutes before the purchase @ just 1.10 pence,providing a price differential of a whopping £23,000.
Meanwhile the larger 5,050,000 tranch showed up as a sale @ 1.50 back in 2016 on Dec 9th.

[mudbath] 07/5/2017 09:00

You must be referring to Bruno Jactel there,PUGUGLY.

[pugugly] 06/5/2017 18:50

michaelsadvfn: Been having another look at trades - In particular those on the 24th April
Both were Y trades. 2,500,000 at 1.3p at 12:54:22 and 1,000,000 at 1.4p earlier. Y trade definition is Late Trade as well over nms - Just wondering if the 1 million was a buy and the 2.5 million was a sell. Price difference suggests may have been.


If this is so then MM's books about balanced as I read (imo) the 2x 2.5 million at 1.379p and 1.38p respectively on 29th April as a pre-agreed off market trade between institutions (or wealthy PI's) as only some £34,500 each way.

That is unless there is still a large seller wanting to unload and thus a big overhang still waiting to clear - Results on Tuesday and subsequent price/volume action will tell either way.

Could be a potential blood bath or champage all round - Binary bet (imo) but which way .....GOK........ ????????????????

[michaelsadvfn] 06/5/2017 16:00

Keep on monitoring guys, the feedback is appreciated.

mudbath,
Regarding TYR, if you go back to mid April there were 2x2.5m + a 1m sell, so 6m in total. Just short of 4m have been absorbed so they still have a few to shift at the current 1.45/1.50.

Roll on Tuesday, if Q1 has gone well we might finally have something to cheer about.

[mudbath] 06/5/2017 15:37

Nobbygnome
Not sad at all for I too perform similar duties at Superdrug.

Fwiw,I like the BOD at Tyratech and the fact that it is a USA domiciled company.Its products do seem relevant to our increasingly ecological focused thinking and the markets which these are targeting are immense.
All to play for then.
I am sure there is something going on with the TYR line of restricted stock with the quote remaining unchanged no matter how significant the number of buys and sells.

Tuesday should be interesting.

[nobbygnome] 06/5/2017 13:31

FWIW my local Lloyds sold at least 3 boxes this week and Boots 1. I am now regularly moving stock forward to the front of the shelf so doing the shop assistants' job for them! So whoever was complaining about the sales per shelf space would be satisfied with 3 in a week!

I also 'watch' sales on Amazon when they say a certain number are left in stock. For example 5 packs of 2 x shampoos were sold in 10 days (1 of those was bought by me!). Also regularly the adverts say more coming and then it goes from a number to ' in stock '. So whoever the supplier is on Amazon, they are regularly reordering.

Some may think it is a bit sad of me monitoring this but it does give you some perspective that stock is moving.

Nobby

[professor pettigrew] 04/5/2017 19:29

Actually - it's me. I've been following "michaels" tips over the years.

They are spot on.

I own 100m.

[mudbath] 04/5/2017 17:20

The quote on a dummy order in size narrowed today from 1.3/1.45 to 1.35/1.45 PUGUGLY.
I construed this as a positive,precipitating both my flipping and adding trades.

[pugugly] 04/5/2017 16:58

mud - does not appear to compute with trades TYR buys (assuming alogs correct) went through at 1.45 (bid/offer at 1.25/1.5) and TYRU at 1.8 (bid offer 1.75/2.0) No 1.35 bid that I can see no 1 million trade on either - So "leg pull?"

[mudbath] 04/5/2017 16:47

Its me Nobbygnome for I got all fired up when they raised the bid to 1.35 for 1 million TYR.
Egg on my face might await me next Tuesday but fingers crossed that might be avoided.

[nobbygnome] 04/5/2017 15:31

It looks like more flipping going on today.... Anyone here care to own up 🤔?

Nobby

[pugugly] 02/5/2017 18:08

ma> Well spotted - I only did a quick glance and missed the 1-2 duplication - Would suggest more likely a switch between institutions a bit large for most PI's but at £40K could be one of the larger PI's.

[michaelsadvfn] 02/5/2017 14:26

I believe it was 5.8m, 2.9m @ 1.375 & 2.9m @ 1.38 although ADVFN is showing trade 0 & trade 1 twice.

I wondered about those 2 trades which, on the surface, look like a rollover, but at mid price?

History now anyway.

[pugugly] 02/5/2017 13:50

10 million TYR changed hands on Friday - Question has news leaked ??

[mudbath] 02/5/2017 12:24

The restricted TYR shares remain weak,enabling me to add today at a record low of 1.45 pence.I hope this is not a company in which the angels fear to tread.

[nobbygnome] 02/5/2017 10:58

It seems to me the weakness in TYRU is due to flippers. Yes there has been a seller of TYR which has allowed this but the weakness of the more frequently traded TYRU appears to be purely technical.

Just IMHO of course....

Nobby

[clocktower] 02/5/2017 10:40

Mud do you use a "sprat to catch a mackerel" ?